J Korean Med Sci.  2021 Oct;36(41):e287. 10.3346/jkms.2021.36.e287.

National Academy of Medicine of Korea (NAMOK) Key Statements on COVID-19

• Shin HS
• Park H
• Kwon JS
• Namgoong H
• Kim SJ
• Kim JM
• Peck KR
• Lee K
• Lee Jk
• Lee J
• Han HC
• Hong S
• Park BJ
• Lim TH
• Hwang ES
• Woo JH
• NAMOK COVID-19 Committee

• KMID: 2521468
• DOI: http://doi.org/10.3346/jkms.2021.36.e287

Figure

• 

  Fig. 1 National coronavirus disease 2019 testing results.KSLM = Korean Society for Laboratory Medicine.Source: Korean Society for Laboratory Medicine; as of April 2, 2021.

• 

  Fig. 2 Metropolitan free screening center testing performance (December 14, 2020–February 7, 2021).

• 

  Fig. 3 Status of confirmed cases, critically ill cases, and deaths during the first coronavirus disease 2019 pandemic in Korea. There is no information on critically ill patients during the early stages of the COVID-19 outbreak in the government data. The Korean Society of Critical Care Medicine collected critical care data from March 9, focusing on training hospitals specializing in critical care medicine. In this graph, critical patients are those requiring mechanical ventilation.

• 

  Fig. 4 Status of confirmed cases, critically ill cases, and deaths during the second and third coronavirus disease 2019 pandemics. In this graph, critical patients are those requiring high-flow oxygen therapy, mechanical ventilation, extracorporeal membrane oxygenation, continuous renal replacement therapy, etc.

• 

  Fig. 5 Coronavirus disease 2019 inpatient trends in the UK (7-day average).27 Source: European CDC for EU countries, government sources for other countries.

• 

  Fig. 6 Distribution of critically ill coronavirus disease 2019 patients receiving mechanical ventilation during the first pandemic.

• 

  Fig. 7 Assignment guidelines for critical care beds.Source: 2020, Society of Critical Care Medicine.

• 

  Fig. 8 Psychiatric symptoms found among therapists.34 PTSD = posttraumatic stress disorder.

• 

  Fig. 9 Underlying psychiatric disorders, use of antipsychotics, and SARS-CoV-2.43 OR = odd ratio, CI = confidence interval, SARS-CoV-2 = severe acute respiratory syndrome-coronavirus-2, COVID-19 = coronavirus diseases 2019.

• 

  Fig. 10 Seven tips to keep your mind healthy through coronavirus diseases 2019.Source: The Trauma Center of the National Center for Mental Health.

• 

  Fig. 11 Coronavirus diseases 2019 situation.45

Reference

1. Korean Society for Laboratory Medicine. Updated 2021. Accessed August 5, 2021. https://www.kslm.org/popup/popup_201222_02.html.

2. Kohmer N, Toptan T, Pallas C, Karaca O, Pfeiffer A, Westhaus S, et al. The comparative clinical performance of four SARS-CoV-2 rapid antigen tests and their correlation to infectivity in vitro. J Clin Med. 2021; 10(2):328. PMID: 33477365.

3. World Health Organization. Antigen-detection in the Diagnosis of SARS-CoV-2 Infection Using Rapid Immunoassays. Geneva, Switzerland: WHO;2020.

4. European Centre for Disease Prevention and Control. Options for the Use of Rapid Antigen Tests for COVID-19 in the EU/EEA and the UK. 19 November 2020. Stockholm, Sweden: ECDC;2020.

5. Barat B, Das S, De Giorgi V, Henderson DK, Kopka S, Lau AF, et al. Pooled saliva specimens for SARS-CoV-2 testing. J Clin Microbiol. 2021; 59(3):e02486–e02420. PMID: 33262219.

6. The Korean Society for Laboratory Medicine COVID-19 Response Task Force, Korea Disease Control and Prevention Agency Infectious Disease Diagnosis and Analysis Bureau. Guidelines for the Laboratory Diagnosis of COVID-19 in Korea. Vol. 4. Updated 2020. Accessed August 5, 2021. https://www.kslm.org/.

7. Kim SY, Lee J, Sung H, Lee H, Han MG, Yoo CK, et al. Pooling upper respiratory specimens for rapid mass screening of COVID-19 by real-time RT-PCR. Emerg Infect Dis. 2020; 26(10):2469–2472. PMID: 32844739.

8. National Academy of Medicine of Korea and The Korean Federation of Science and Technology Societies 16^th Online Joint Forum. COVID-19 diagnosis test for successful K quarantine. December 22, 2020. Updated 2020. Accessed August 5, 2021. https://youtu.be/MucEP9Iqx6Q.

9. Korea Disease Control and Prevention Agency. Final judgment of false-positive results for 3 suspected cases of COVID-19 in Gwangju and Chungnam. Updated 2020. Accessed August 5, 2021. https://kdca.go.kr/board/board.es?mid=a20501000000&bid=0015&list_no=367517&cg_code=&act=view&nPage=1.

10. The New York Times. C.D.C. warns the new virus variant could fuel huge spikes in Covid-19 cases. Updated 2021. Accessed August 5, 2021. https://www.nytimes.com/2021/01/15/health/covid-cdc-variant.html.

11. Nextstrain. Genomic epidemiology of novel coronavirus - Global subsampling. Updated 2021. Accessed September 2, 2021. https://nextstrain.org/ncov/global.

12. GISAID. GISAID comments on the discussion of different types or clades of the hCoV-19 virus and their origin. Updated 2020. Accessed February 21, 2021. https://www.gisaid.org/references/statements-clarifications/different-types-or-clades-of-the-virus-and-their-origin/#c501.

13. Lee H, Lee H, Song KH, Kim ES, Park JS, Jung J, et al. Impact of public health interventions on seasonal influenza activity during the SARS-CoV-2 outbreak in Korea. Clin Infect Dis. 2021; 73(1):e132–e140. PMID: 32472687.

14. Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020; 34(2):75–80. PMID: 32107119.

15. Hussein HA, Hassan RYA, Chino M, Febbraio F. Point-of-care diagnostics of COVID-19: From current work to future perspectives. Sensors (Basel). 2020; 20(15):4289.

16. Korea Disease Control and Prevention Agency. Starting the Development of New Coronavirus Analysis and Inspection Methods. Cheongju, Korea: Korea Disease Control and Prevention Agency;2020.

17. Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020; 78(4):779–784.e5. PMID: 32362314.

18. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020; 368(6493):860–868. PMID: 32291278.

19. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020; 181(4):914–921.e10. PMID: 32330414.

20. Heo JY. Clinical and epidemiological characteristics of coronavirus disease 2019 in the early stage of outbreak. Korean J Med. 2020; 95(2):67–73.

21. National Academy of Medicine of Korea and The Korean Federation of Science and Technology Societies 4^th Online Joint Forum. How far has COVID-19 therapeutic and vaccine development progressed? April 17, 2020. Updated 2020. Accessed March 2, 2021. https://www.youtube.com/watch?v=1XgnQUcWIts.

22. National Academy of Medicine of Korea and The Korean Federation of Science and Technology Societies 10^th Online Joint Forum. Current status on the development of COVID-19 therapeutics. September 25, 2020. Updated 2020. Accessed March 2, 2021. https://www.youtube.com/watch?v=o_RU75W4xP8.

23. World Health Organization. The COVID-19 candidate vaccine landscape and tracker. Updated 2021. Accessed February 21, 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

24. Jung J. Preparing for the coronavirus disease (COVID-19) vaccination: Evidence, plans, and implications. J Korean Med Sci. 2021; 36(7):e59. PMID: 33619920.

25. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021; 325(8):780–781. PMID: 33475702.

26. Sung HK, Kim JY, Heo J, Seo H, Jang YS, Kim H, et al. Clinical course and outcomes of 3,060 patients with coronavirus disease 2019 in Korea, January–May 2020. J Korean Med Sci. 2020; 35(30):e280. PMID: 32743995.

27. Eurosurveillance Editorial Team. Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update. Euro Surveill. 2021; 26(3):2101211.

28. National Academy of Medicine of Korea and The Korean Federation of Science and Technology Societies 6^th Online Joint Forum. COVID-19 experience in Daegu and Gyeongbuk areas and response plans. June 19, 2020. Updated 2020. Accessed July 19, 2021. https://www.youtube.com/watch?v=Xn6VTRtXOZs&t=133s.

29. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020; 382(21):2049–2055. PMID: 32202722.

30. Pfefferbaum B, North CS. Mental health and the Covid-19 pandemic. N Engl J Med. 2020; 383(6):510–512. PMID: 32283003.

31. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020; 89:531–542. PMID: 32485289.

32. Ma YF, Li W, Deng HB, Wang L, Wang Y, Wang PH, et al. Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19. J Affect Disord. 2020; 275:145–148. PMID: 32658818.

33. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7(7):611–627. PMID: 32437679.

34. Chew NW, Lee GK, Tan BY, Jing M, Goh Y, Ngiam NJ, et al. A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during COVID-19 outbreak. Brain Behav Immun. 2020; 88:559–565. PMID: 32330593.

35. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020; 3(9):e2019686. PMID: 32876685.

36. Wang Y, Shi L, Que J, Lu Q, Liu L, Lu Z, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry. Forthcoming. 2021; DOI: 10.1038/s41380-021-01019-y.

37. Xiong J, Lipsitz O, Nasri F, Lui LM, Gill H, Phan L, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020; 277:55–64. PMID: 32799105.

38. Liu CH, Zhang E, Wong GT, Hyun S, Hahm HC. Factors associated with depression, anxiety, and PTSD symptomatology during the COVID-19 pandemic: Clinical implications for U.S. young adult mental health. Psychiatry Res. 2020; 290:113172. PMID: 32512357.

39. Nissen JB, Højgaard DR, Thomsen PH. The immediate effect of COVID-19 pandemic on children and adolescents with obsessive compulsive disorder. BMC Psychiatry. 2020; 20(1):511. PMID: 33081741.

40. Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020; 87:100–106. PMID: 32353518.

41. El Haj M, Altintas E, Chapelet G, Kapogiannis D, Gallouj K. High depression and anxiety in people with Alzheimer’s disease living in retirement homes during the covid-19 crisis. Psychiatry Res. 2020; 291:113294. PMID: 32763552.

42. Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020; 7(12):1025–1031. PMID: 32950066.

43. Jeon HL, Kwon JS, Park SH, Shin JY. Association of mental disorders with SARS-CoV-2 infection and severe health outcomes: nationwide cohort study. Br J Psychiatry. Forthcoming. 2021; DOI: 10.1192/bjp.2020.251.

44. World Health Organization. Republic of Korea. Updated 2021. Accessed April 12, 2021. https://covid19.who.int/region/wpro/country/kr.

45. World Health Organization. Weekly epidemiological update – 2 March 2021. Updated 2021. Accessed March 5, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update---2-march-2021.

46. Sachs J, Schmidt-Traub G, Kroll C, Lafortune G, Fuller G, Woelm F. The sustainable development goals and COVID-19. Sustainable development report 2020. Updated 2021. Accessed March 8, 2021. https://s3.amazonaws.com/sustainabledevelopment.report/2020/2020_sustainable_development_report.pdf.

47. OECD. Flattening the COVID-19 peak: containment and mitigation policies. Updated 2020. Accessed March 8, 2021. https://www.oecd.org/coronavirus/policy-responses/flattening-the-covid-19-peak-containment-and-mitigation-policies-e96a4226.

48. The Government of the Republic of Korea. Flattening the curve on COVID-19: How Korea responded to a pandemic using ICT. Updated 2020. Accessed March 8, 2021. http://overseas.mofa.go.kr/gr-en/brd/m_6940/view.do?seq=761548.

49. Lee JK, Bullen C, Ben Amor Y, Bush SR, Colombo F, Gaviria A, et al. Institutional and behaviour-change interventions to support COVID-19 public health measures: a review by the Lancet Commission Task Force on public health measures to suppress the pandemic. Int Health. 2021; 13(5):399–409. PMID: 33974687.

50. World Health Organization. Communicating and managing uncertainty in the COVID-19 pandemic: a quick guide. Updated 2020. Accessed March 8, 2021. https://www.who.int/docs/default-source/searo/whe/coronavirus19/managing-uncertainty-in-covid-19-a-quick-guide.pdf?sfvrsn=270e4ac8_4.

51. Oh J. Roles of insurance for a sustainable society amid disasters. Living with COVID-19 (2020.7.9.). Updated 2020. Accessed March 8, 2021. https://www.youtube.com/watch?v=vUoO5d2GI4w.